Given this backdrop, the adjunctive use of ferroptosis inducers might offer a therapeutic advantage, particularly as dedifferentiated cancer cell phenotypes, with their accentuated ferroptotic sensitivity, come into focus, where GPX4 emerges as a pivotal mediator [74, 115, 172, 173]. This evidence concerns the gene GPX4 and cancer.